@Redeye_ Redeye

Redeye posts on X about comments, ceo, strong, $lagr the most. They currently have [------] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

Engagements: [-----] #

• [--] Week [------] +71%
• [--] Month [------] +69%
• [--] Months [-------] -22%
• [--] Year [---------] -10%

Mentions: [--] #

• [--] Week [--] +78%
• [--] Month [---] -1.20%
• [--] Months [-----] -3%
• [--] Year [-----] +57%

Followers: [------] #

• [--] Week [------] +0.01%
• [--] Month [------] -0.15%
• [--] Months [------] -0.52%
• [--] Year [------] -1.30%

CreatorRank: [-------] #

Social Influence

Social category influence cryptocurrencies 14.29% stocks 8.93% finance 4.46% exchanges #4278 countries 0.89%

Social topic influence comments #2959, ceo #4259, strong 9.82%, $lagr 4.46%, $geno 3.57%, growth 3.57%, q4 #42, $avt #7, $embrac #4, $ray #10

Top accounts mentioned or mentioned by @augustv71950006 @smarteyeab @mrchaarless

Top assets mentioned Aventus (AVT) Raydium (RAY) Nitro League (NITRO) Evotec SE (EVO) Cemex S.A.B. de C.V. (CX) iMe Lab (LIME) MobileCoin (MOB) CatCoin (CAT) Biconomy (BICO) Annexon, Inc. (ANNX) BioAge Labs, Inc. (BIOA) Fusionist (ACE) Inspect (INSP)

Top Social Posts

Top posts by engagements in the last [--] hours

"NanoEcho utvecklar framtidens rektalcancerdiagnostik. Idag startar teckningsperioden i bolagets fretrdesemission p upp till [----] MSEK fr att ta nsta steg med sin PoC-studie. Ls mer om transaktionen: Se VD Linda Perssons hisspitch: https://www.redeye.se/video/transaction/1149074/nanoecho-hisspitchutm_source=twitter&utm_medium=social&utm_campaign=nefeq126&utm_content=image https://www.redeye.se/transaction/nanoecho-ab-(publ)-utm_source=twitter&utm_medium=social&utm_campaign=nefeq126&utm_content=image"
X Link 2026-02-13T10:01Z 14.4K followers, [---] engagements

"Redeye updates its view following Ferroamps strong Q4 report which showed 95% sales growth and materially lower costs highlighting clear operational leverage. $FERRO https://www.redeye.se/research/1150632/ferroamp-q4-review-positioned-for-financial-inflection-in-2026 https://www.redeye.se/research/1150632/ferroamp-q4-review-positioned-for-financial-inflection-in-2026"
X Link 2026-02-16T07:58Z 14.4K followers, [---] engagements

"Redeye updates on Embracer after its Q3-results which were stronger-than-expected while the updated guidance excluding Coffee Stain was largely as anticiapted. $EMBRAC https://www.redeye.se/research/1150660/embracer-q3-review-stable-near-term-outlook-game-pipeline-supports-upside-in-2026-27e https://www.redeye.se/research/1150660/embracer-q3-review-stable-near-term-outlook-game-pipeline-supports-upside-in-2026-27e"
X Link 2026-02-16T08:01Z 14.4K followers, [---] engagements

"Redeye comments on RaySearch's Q4 beating our sales estimates and came in line with our EBIT forecast. $RAY https://www.redeye.se/research/1150520/raysearch-laboratories-q4-review-a-beaming-end-it-was https://www.redeye.se/research/1150520/raysearch-laboratories-q4-review-a-beaming-end-it-was"
X Link 2026-02-16T08:03Z 14.4K followers, [---] engagements

"Redeye comments on Nitro Games Q4-results which where stronger-than-expected driven by solid profitability while topline was close to our forecast. $NITRO https://www.redeye.se/research/1150692/nitro-games-q4-initial-take-solid-beat-driven-by-strong-profitability https://www.redeye.se/research/1150692/nitro-games-q4-initial-take-solid-beat-driven-by-strong-profitability"
X Link 2026-02-16T08:06Z 14.4K followers, [---] engagements

"Redeye comments on BONESUPPORT preliminary sales being known at SEK313m and we forecast a SEK62m EBIT corresponding to a 20% margin. $BONEX https://www.redeye.se/research/1150905/bonesupport-q4-preview-adding-to-the-preliminary-sales-figures https://www.redeye.se/research/1150905/bonesupport-q4-preview-adding-to-the-preliminary-sales-figures"
X Link 2026-02-16T12:36Z 14.4K followers, [---] engagements

"Redeye comments on Calliditas' recent patent notice and its impact ahead of the critical PDUFA date on [--] December. $CALTX https://www.redeye.se/research/967210/calliditas-patent-notice-ahead-of-the-key-pdufa-date-on-20th-december https://www.redeye.se/research/967210/calliditas-patent-notice-ahead-of-the-key-pdufa-date-on-20th-december"
X Link 2023-12-14T12:54Z 14.4K followers, [----] engagements

"Redeye har intervjuat Active Biotechs vd Heln Tuvesson om Q4 rapporten med ett fokus p nyemissionen tasquinimod och laquinimod. $ACTI https://www.redeye.se/research/1149396/active-biotech-q4-intervju-redeye-pratar-med-vd-helen-tuvesson https://www.redeye.se/research/1149396/active-biotech-q4-intervju-redeye-pratar-med-vd-helen-tuvesson"
X Link 2026-02-12T13:47Z 14.4K followers, [---] engagements

"Redeye has interviewed Stille's CEO Ulrik Berthelsen following the company's year-end report which showed a beat compared to Redeye's estimates across the board. $STIL https://www.redeye.se/research/1149291/stille-q4-interview-redeye-speaks-with-ceo-ulrik-berthelsen https://www.redeye.se/research/1149291/stille-q4-interview-redeye-speaks-with-ceo-ulrik-berthelsen"
X Link 2026-02-12T13:49Z 14.4K followers, [---] engagements

"Redeye retains its positive view of Carasent following the Q4 report. $CARA https://www.redeye.se/research/1148481/carasent-q4-review-new-products-and-sales-initiatives-to-drive-growth-in-2026 https://www.redeye.se/research/1148481/carasent-q4-review-new-products-and-sales-initiatives-to-drive-growth-in-2026"
X Link 2026-02-16T07:57Z 14.4K followers, [---] engagements

"Redeye returns with an updated view following Nekkars Q4 figures that posted a welcome recovery. $NKR https://www.redeye.se/research/1150579/nekkar-q4-review-new-deals-and-tender-pipeline-support-rebound https://www.redeye.se/research/1150579/nekkar-q4-review-new-deals-and-tender-pipeline-support-rebound"
X Link 2026-02-16T08:01Z 14.4K followers, [---] engagements

"Redeye comments on Mendus Q4 report we have updated our valuation scenarios and present a new base case. $IMMU https://www.redeye.se/research/1150785/mendus-q4-review-cml-a-new-value-driver https://www.redeye.se/research/1150785/mendus-q4-review-cml-a-new-value-driver"
X Link 2026-02-16T14:29Z 14.4K followers, [---] engagements

"Redeye updates on Nitro Games after Q4-results which were better than expected owing to strong profitability while revenue was in line with our forecast. $NITRO https://www.redeye.se/research/1151232/nitro-games-q4-review-solid-year-end-performance https://www.redeye.se/research/1151232/nitro-games-q4-review-solid-year-end-performance"
X Link 2026-02-17T07:01Z 14.4K followers, [---] engagements

"Redeye comments on Genovis' Q4 [----] report showing strong growth following the SEK10.9m ADC order as expected. $GENO https://www.redeye.se/research/1148620/genovis-q4-review-growth-and-a-big-cash-pile-at-rapidly-contracting-multiples https://www.redeye.se/research/1148620/genovis-q4-review-growth-and-a-big-cash-pile-at-rapidly-contracting-multiples"
X Link 2026-02-17T07:08Z 14.4K followers, [---] engagements

"Redeye comments on Xspray after a year marked by both progress and setbacks with two upcoming PDUFA decisions followed by the potential launches of its lead candidates Dasynoc and XS003. $XSPRAY https://www.redeye.se/research/1146648/xspray-pharma-q4-review-a-pivotal-year-ahead https://www.redeye.se/research/1146648/xspray-pharma-q4-review-a-pivotal-year-ahead"
X Link 2026-02-17T07:10Z 14.4K followers, [---] engagements

"Redeye provides its initial take on Moberg Pharmas Q4 report where sales greatly exceeded our expectations. $MOB https://www.redeye.se/research/1150372/moberg-pharma-q4-initial-take-sales-ahead-of-forecast https://www.redeye.se/research/1150372/moberg-pharma-q4-initial-take-sales-ahead-of-forecast"
X Link 2026-02-17T07:59Z 14.4K followers, [---] engagements

"Redeye views Catella's Q4 [----] results as broadly reassuring Investment Management delivered a revenue beat despite AUM coming in below estimate whilst Corporate Finance demonstrated underlying momentum once the SEK51m non-recurring divestment gain is stripped out. $CAT https://www.redeye.se/research/1151003/catella-q4-initial-take-clean-core-beat-clouded-by-sek151m-kotower-impairment https://www.redeye.se/research/1151003/catella-q4-initial-take-clean-core-beat-clouded-by-sek151m-kotower-impairment"
X Link 2026-02-17T08:07Z 14.4K followers, [---] engagements

"Redeye has interviewed Boreos CEO Kari Nerg. $BOREO https://www.redeye.se/research/1150883/boreo-q4-interview-redeye-speaks-with-ceo-kari-nerg https://www.redeye.se/research/1150883/boreo-q4-interview-redeye-speaks-with-ceo-kari-nerg"
X Link 2026-02-16T12:34Z 14.4K followers, [---] engagements

"Redeye provides a preview of its estimates ahead of BICOs Q4 results scheduled for release on November [--]. $BICO https://www.redeye.se/research/1150888/bico-q4-preview-recalibration-ahead-of-the-report https://www.redeye.se/research/1150888/bico-q4-preview-recalibration-ahead-of-the-report"
X Link 2026-02-16T12:49Z 14.4K followers, [---] engagements

"Redeye provides an initial take following the release of Corlines Q4 [----] report. $CLBIO https://www.redeye.se/research/1151330/corline-biomedical-q4-initial-take-waiting-for-the-sales-ramp-up https://www.redeye.se/research/1151330/corline-biomedical-q4-initial-take-waiting-for-the-sales-ramp-up"
X Link 2026-02-17T08:47Z 14.4K followers, [---] engagements

"We are LIVE with Modelon Management of Modelon presents the companys quarterly report followed by a Q&A moderated by Redeyes analyst. Tune in: https://www.redeye.se/events/1144728/live-q-modelon-7 https://www.redeye.se/events/1144728/live-q-modelon-7"
X Link 2026-02-17T10:57Z 14.4K followers, [---] engagements

"Redeye's view of Genovis Q2 report is balanced sales were largely in line but profitability was softer than we had estimated. $GENO http://redeye.se/research/1121748/genovis-q2-2025-initial-comments http://redeye.se/research/1121748/genovis-q2-2025-initial-comments"
X Link 2025-08-12T08:49Z 14.4K followers, [----] engagements

"Redeye notes an interesting press release from Genovis confirming a SEK11m order from a global pharmaceutical company. $GENO https://www.redeye.se/research/1131032/genovis-eur1m-order-strengthening-the-outlook https://www.redeye.se/research/1131032/genovis-eur1m-order-strengthening-the-outlook"
X Link 2025-10-20T05:00Z 14.4K followers, [----] engagements

"Redeye has interviewed Lagercrantzs CEO Jrgen Wigh. $LAGR https://www.redeye.se/research/1132817/lagercrantz-q2-interview-redeye-speaks-with-ceo-jorgen-wigh https://www.redeye.se/research/1132817/lagercrantz-q2-interview-redeye-speaks-with-ceo-jorgen-wigh"
X Link 2025-10-24T11:32Z 14.4K followers, [---] engagements

"Redeye updates its estimates and valuation after Lagercrantzs Q2 2025/2026 report. $LAGR https://www.redeye.se/research/1133217/lagercrantz-q3-review-strong-ma-pipeline https://www.redeye.se/research/1133217/lagercrantz-q3-review-strong-ma-pipeline"
X Link 2025-10-27T08:52Z 14.4K followers, [---] engagements

"Redeye reviews SynAct Pharma's Q3 report. $SYNACT https://www.redeye.se/research/1133751/synact-q3-update-advance-approaching-full-recruitment https://www.redeye.se/research/1133751/synact-q3-update-advance-approaching-full-recruitment"
X Link 2025-10-31T07:35Z 14.4K followers, [---] engagements

"Redeye comments on Embracers Q2-results which were somewhat better than expected driven largely by Entertainment & Services while PC/Console and Mobile were close to our forecasts. $EMBRAC https://www.redeye.se/research/1138700/embracer-q2-initial-take-somewhat-above-expectations-guidance-unchanged https://www.redeye.se/research/1138700/embracer-q2-initial-take-somewhat-above-expectations-guidance-unchanged"
X Link 2025-11-13T08:34Z 14.4K followers, [----] engagements

"Redeye takes a positive stance towards Vertiseits acquisition of Muse expanding the offering into a new related area which is going through a major transformation. $VERT https://www.redeye.se/research/1140069/vertiseit-entering-audio-as-ai-transforms-the-market https://www.redeye.se/research/1140069/vertiseit-entering-audio-as-ai-transforms-the-market"
X Link 2025-11-20T14:00Z 14.4K followers, [---] engagements

"Vitrolife is trading below Redeyes Bear Case. We spoke with our analyst about what drives Vitrolife's competitive position in the global IVF market how sustainable gross margins above 60% are in core segments and other key topics. This is a premium article included in our paid plans from SEK 99/month. $VITR https://www.redeye.se/research/1146054/vitrolife https://www.redeye.se/research/1146054/vitrolife"
X Link 2026-01-27T09:17Z 14.4K followers, [---] engagements

"Redeye provides its initial take on Indutrades Q4 [----] report which missed on earnings mainly due to two relatively large project write-downs in the UK. $INDT https://www.redeye.se/research/1146294/indutrade-q4-initial-take-project-write-downs-hurt-ebita https://www.redeye.se/research/1146294/indutrade-q4-initial-take-project-write-downs-hurt-ebita"
X Link 2026-01-29T17:38Z 14.4K followers, [---] engagements

"Redeye provides its initial take on Lifcos Q4 [----] report which missed our projections by 3% on sales and 5% on EBITA. $LIFCO https://www.redeye.se/research/1146457/lifco-q4-initial-take-slight-miss-driven-by-dental-and-demolition-tools https://www.redeye.se/research/1146457/lifco-q4-initial-take-slight-miss-driven-by-dental-and-demolition-tools"
X Link 2026-02-02T06:00Z 14.4K followers, [---] engagements

"Redeye comments on Vitrolifes Q4 report coming in very close to our projections reflecting modest underlying growth and a significant reported EBIT loss driven by the goodwill impairment announced in December. $VITR https://www.redeye.se/research/1145964/vitrolife-q4-initial-take-aligned-nicely-with-estimates https://www.redeye.se/research/1145964/vitrolife-q4-initial-take-aligned-nicely-with-estimates"
X Link 2026-02-03T08:48Z 14.4K followers, [---] engagements

"Redeye has interviewed SynAct Pharma's CSO Thomas Jonassen about a new investigator-sponsored phase II study of resomelagon in viral infections. $SYNACT https://www.redeye.se/research/1146848/synact-pharma-interview-redeye-speaks-with-cso-thomas-jonassen https://www.redeye.se/research/1146848/synact-pharma-interview-redeye-speaks-with-cso-thomas-jonassen"
X Link 2026-02-03T13:17Z 14.4K followers, [---] engagements

"Redeye updates its estimates and valuation after Lifcos Q4 [----] report. $LIFCO https://www.redeye.se/research/1146626/lifco-q4-review-steady-as-she-goes https://www.redeye.se/research/1146626/lifco-q4-review-steady-as-she-goes"
X Link 2026-02-04T08:01Z 14.4K followers, [---] engagements

"Redeye comments on the current valuation profile of Vitrolife requiring more than the current stagnant growth profile yesterdays 20% sell-off (despite a report largely in line with Redeyes estimates) appears excessive. $VITR https://www.redeye.se/research/1140910/vitrolife-q4-review-excessive-selloff-improves-risk-reward-in-the-stock https://www.redeye.se/research/1140910/vitrolife-q4-review-excessive-selloff-improves-risk-reward-in-the-stock"
X Link 2026-02-04T08:02Z 14.4K followers, [---] engagements

"Redeye comments on Hexatronics Q4 report showing solid overall numbers driven by a further acceleration in Data Center. $HTRO https://www.redeye.se/research/1146077/hexatronic-q4-initial-take-strong-adjusted-numbers-accelerating-growth-in-data-center https://www.redeye.se/research/1146077/hexatronic-q4-initial-take-strong-adjusted-numbers-accelerating-growth-in-data-center"
X Link 2026-02-05T08:12Z 14.4K followers, [---] engagements

"Redeye comments on Evolutions Q4-results which were close to our forecasts albeit with soft revenue in Europe while LatAm and Asia were slightly stronger than expected. $EVO https://www.redeye.se/research/1147410/evolution-q4-initial-take-close-to-our-expectations https://www.redeye.se/research/1147410/evolution-q4-initial-take-close-to-our-expectations"
X Link 2026-02-05T08:14Z 14.4K followers, [----] engagements

"Redeye comments on Fractal Gaming Groups Q4 [----] report which came in below our expectations. $FRACTL https://www.redeye.se/research/1145586/fractal-q4-initial-take-tough-macro-weighs-on-profitability https://www.redeye.se/research/1145586/fractal-q4-initial-take-tough-macro-weighs-on-profitability"
X Link 2026-02-05T08:14Z 14.4K followers, [---] engagements

"Redeye considers I-Tech's Q4 report to be soft although the company faced relatively high set expectations and tough comps. $ITECH https://www.redeye.se/research/1146854/i-tech-q4-initial-take-softer-than-expected-top-line https://www.redeye.se/research/1146854/i-tech-q4-initial-take-softer-than-expected-top-line"
X Link 2026-02-05T09:07Z 14.4K followers, [---] engagements

"Redeye has interviewed Hexatronic's CEO Rikard Frberg about the fourth quarter and how the company manages to growth fast within Data Center. $HTRO https://www.redeye.se/research/1147202/hexatronic-q4-interview-redeye-speaks-with-ceo-rikard-froberg https://www.redeye.se/research/1147202/hexatronic-q4-interview-redeye-speaks-with-ceo-rikard-froberg"
X Link 2026-02-05T09:08Z 14.4K followers, [---] engagements

"Redeye presents its preview of RaySearchs Q4 [----] results due on February [--]. $RAY https://www.redeye.se/research/1147593/raysearch-q4-preview-possibilities-for-a-beaming-end-to-2025 https://www.redeye.se/research/1147593/raysearch-q4-preview-possibilities-for-a-beaming-end-to-2025"
X Link 2026-02-05T12:57Z 14.4K followers, [---] engagements

"Redeye updates on Evolution post Q4-results which were close to our forecasts while the companys margin guidance for [----] was also in line with expectations. $EVO https://www.redeye.se/research/1147724/evolution-q4-review-asia-and-europe-continue-to-hold-back-growth https://www.redeye.se/research/1147724/evolution-q4-review-asia-and-europe-continue-to-hold-back-growth"
X Link 2026-02-06T08:26Z 14.4K followers, [----] engagements

"Redeye comments on Vitecs Q4 report. $VIT https://www.redeye.se/research/1146086/vitec-q4-initial-take-clearly-beating-modest-expectations https://www.redeye.se/research/1146086/vitec-q4-initial-take-clearly-beating-modest-expectations"
X Link 2026-02-06T08:27Z 14.4K followers, [---] engagements

"Redeye provides its initial take on CTEKs Q4 numbers where sales were slightly lower than expected but profitability greatly exceeded our expectations. $CTEK https://www.redeye.se/research/1147826/ctek-q4-initial-take-higher-profit-levels-than-expected https://www.redeye.se/research/1147826/ctek-q4-initial-take-higher-profit-levels-than-expected"
X Link 2026-02-06T08:28Z 14.4K followers, [---] engagements

"Redeye provides its initial take on Lagercrantzs Q3 2025/2026 report which showed strong EBITA growth of 20% y/y beating our forecast by 5%. $LAGR https://www.redeye.se/research/1147841/lagercrantz-q3-initial-take-strong-numbers-raised-ambition https://www.redeye.se/research/1147841/lagercrantz-q3-initial-take-strong-numbers-raised-ambition"
X Link 2026-02-06T08:30Z 14.4K followers, [---] engagements

"Redeye comments on Annexins Q4 report and recent events and see good initial progress in the phase II study. $ANNX https://www.redeye.se/research/1147539/annexin-pharmaceuticals-q4-review-phase-ii-study-away-with-positive-initial-results https://www.redeye.se/research/1147539/annexin-pharmaceuticals-q4-review-phase-ii-study-away-with-positive-initial-results"
X Link 2026-02-06T13:57Z 14.4K followers, [---] engagements

"Redeye takes a slightly more positive view following Hexatronic's Q4 report showing even stronger momentum in Data Center. $HTRO https://www.redeye.se/research/1146071/hexatronic-q4-review-in-good-shape-for-2026 https://www.redeye.se/research/1146071/hexatronic-q4-review-in-good-shape-for-2026"
X Link 2026-02-06T14:01Z 14.4K followers, [---] engagements

"Redeye comments on Fractals share price falling sharply as the market prices in prolonged weakness in PC demand and elevated uncertainty around profitability in [----]. $FRACTL https://www.redeye.se/research/1145688/fractal-gaming-group-q4-review-patience-will-be-rewarded https://www.redeye.se/research/1145688/fractal-gaming-group-q4-review-patience-will-be-rewarded"
X Link 2026-02-06T14:03Z 14.4K followers, [---] engagements

"Redeye strengthens its positive view of Vitec following the Q4 report. $VIT https://www.redeye.se/research/1146081/vitec-q4-review-solid-operations-and-acquisitions-as-usual-in-ai-driven-market-volatility https://www.redeye.se/research/1146081/vitec-q4-review-solid-operations-and-acquisitions-as-usual-in-ai-driven-market-volatility"
X Link 2026-02-09T08:57Z 14.4K followers, [---] engagements

"Redeye har intervjuat CTEKs vd Henrik Fagrenius efter fredagens Q4-rapport som visade lgre omsttning jmfrt med fregende r men en kraftigt frbttrad lnsamhet och ett starkt kassaflde. $CTEK https://www.redeye.se/research/1147995/ctek-q4-intervju-redeye-pratar-med-vd-henrik-fagrenius https://www.redeye.se/research/1147995/ctek-q4-intervju-redeye-pratar-med-vd-henrik-fagrenius"
X Link 2026-02-09T09:01Z 14.4K followers, [---] engagements

"Redeye updates its estimates and valuation after Lagercrantzs Q3 2025/2026 report. $LAGR https://www.redeye.se/research/1148071/lagercrantz-q3-review-demand-is-picking-up https://www.redeye.se/research/1148071/lagercrantz-q3-review-demand-is-picking-up"
X Link 2026-02-09T09:03Z 14.4K followers, [---] engagements

"Redeye comments on SynAct Pharma's full recruitment of the phase IIb ADVANCE study in RA with [---] patients. $SYNACT https://www.redeye.se/research/1148168/synact-pharma-last-patient-included https://www.redeye.se/research/1148168/synact-pharma-last-patient-included"
X Link 2026-02-09T09:04Z 14.4K followers, [---] engagements

"Redeye briefly comments on BioArctic's Q4 royalties for Leqembi which came in roughly as expected. $BIOA https://www.redeye.se/research/1147992/bioarctic-q4-royalties-roughly-in-line https://www.redeye.se/research/1147992/bioarctic-q4-royalties-roughly-in-line"
X Link 2026-02-09T09:05Z 14.4K followers, [---] engagements

"Redeye has interviewed Fractal Gaming Groups CEO Jonas Holst who shares key insights from the Q4 report the current market environment and how the category expansion is unfolding. $FRACTL https://www.redeye.se/research/1147991/fractal-gaming-group-q4-interview-redeye-speaks-with-ceo-jonas-holst https://www.redeye.se/research/1147991/fractal-gaming-group-q4-interview-redeye-speaks-with-ceo-jonas-holst"
X Link 2026-02-09T09:06Z 14.4K followers, [---] engagements

"Redeye has interviewed Lagercrantzs CEO Jrgen Wigh. $LAGR https://www.redeye.se/research/1148227/lagercrantz-q3-interview-redeye-speaks-with-ceo-jorgen-wigh https://www.redeye.se/research/1148227/lagercrantz-q3-interview-redeye-speaks-with-ceo-jorgen-wigh"
X Link 2026-02-09T15:25Z 14.4K followers, [---] engagements

"Redeye returns with an update following Ascelia Pharma's Q4 update which contained no material surprises. $ACE https://www.redeye.se/research/1148258/ascelia-pharma-q4-review-on-the-path-to-approval https://www.redeye.se/research/1148258/ascelia-pharma-q4-review-on-the-path-to-approval"
X Link 2026-02-10T08:44Z 14.4K followers, [---] engagements

"Redeye provides an initial comment on the Q4 [----] report from Sdiptech where adjusted EBITA in core operations came in exactly in line with our forecasts and consensus. $SDIP https://www.redeye.se/research/1148192/sdiptech-q4-initial-take-divestments-are-progressing-adj-ebita-in-line https://www.redeye.se/research/1148192/sdiptech-q4-initial-take-divestments-are-progressing-adj-ebita-in-line"
X Link 2026-02-10T08:45Z 14.4K followers, [---] engagements

"Redeye updates its view following CTEKs Q4 report. $CTEK https://www.redeye.se/research/1148634/ctek-q4-review-2026-a-harvesting-year-for-product-investments https://www.redeye.se/research/1148634/ctek-q4-review-2026-a-harvesting-year-for-product-investments"
X Link 2026-02-11T08:56Z 14.4K followers, [---] engagements

"Redeye provides a research update after Optomeds Q4 [----] report. $OPTOMED https://www.redeye.se/research/1148555/optomed-q4-review-devices-segment-growth-supports-outlook-despite-cautious-guidance https://www.redeye.se/research/1148555/optomed-q4-review-devices-segment-growth-supports-outlook-despite-cautious-guidance"
X Link 2026-02-11T08:56Z 14.4K followers, [---] engagements

"Redeye updates its estimates and valuation following MedCaps Q4 [----] report. $MCAP https://www.redeye.se/research/1148546/medcap-q4-review-beat-on-solid-organic-growth https://www.redeye.se/research/1148546/medcap-q4-review-beat-on-solid-organic-growth"
X Link 2026-02-11T08:57Z 14.4K followers, [---] engagements

"Redeye has interviewed Gapwaves' CEO Jonas Ehinger to unpack a strong Q4 rapidly increasing volumes and what the transition to manufacturing partner Frencken means for margins and the path to profitability. $GAPW https://www.redeye.se/research/1148262/gapwaves-q4-interview-redeye-speaks-with-ceo-jonas-ehinger https://www.redeye.se/research/1148262/gapwaves-q4-interview-redeye-speaks-with-ceo-jonas-ehinger"
X Link 2026-02-11T08:58Z 14.4K followers, [---] engagements

"Redeye updates on EG7 ahead of Q4-results (due [--] February) where we expect the results to remain largely stable compared to Q3 as currency headwind counteracts positive seasonality. $EG7 https://www.redeye.se/research/1148675/eg7-q4-preview-continued-fx-headwind https://www.redeye.se/research/1148675/eg7-q4-preview-continued-fx-headwind"
X Link 2026-02-11T08:59Z 14.4K followers, [---] engagements

"Redeye comments on Hansa Biopharma's Q4 report. $HNSA https://www.redeye.se/research/1148656/hansa-biopharma-q4-initial-take-strong-european-sales-beats-forecast https://www.redeye.se/research/1148656/hansa-biopharma-q4-initial-take-strong-european-sales-beats-forecast"
X Link 2026-02-11T09:44Z 14.4K followers, [---] engagements

"Redeye retains its positive view of CombinedX following the Q4 report. $CX https://www.redeye.se/research/1148430/combinedx-q4-initial-take-solid-underlying-profitability-slightly-revised-strategy https://www.redeye.se/research/1148430/combinedx-q4-initial-take-solid-underlying-profitability-slightly-revised-strategy"
X Link 2026-02-11T09:45Z 14.4K followers, [---] engagements

"Redeye comments briefly on Insplorions announcement following the Boards strategic review. $INSP https://www.redeye.se/research/1148847/insplorion-divesting-its-core-business https://www.redeye.se/research/1148847/insplorion-divesting-its-core-business"
X Link 2026-02-11T14:54Z 14.4K followers, [---] engagements

"Redeye comments on todays press release from Waystream announcing that Telia Estonia has placed a SEK9m follow-up order for access switches. $WAYS https://www.redeye.se/research/1149044/waystream-telia-estonia-scales-up-with-sek9m-order https://www.redeye.se/research/1149044/waystream-telia-estonia-scales-up-with-sek9m-order"
X Link 2026-02-11T15:21Z 14.4K followers, [---] engagements

"Redeye comments on Vertiseits Q4 report showing somewhat lower organic ARR growth and higher OPEX than expected. $VERT https://www.redeye.se/research/1148503/vertiseit-q4-initial-take-somewhat-soft-q4-positive-outlook https://www.redeye.se/research/1148503/vertiseit-q4-initial-take-somewhat-soft-q4-positive-outlook"
X Link 2026-02-12T09:10Z 14.4K followers, [---] engagements

"Redeye comments on Devyser reaching a 25% EBIT margin and record sales with strong operating cash flow. We expect the share to trade upwards 15% today. $DVYSR https://www.redeye.se/research/1149167/devyser-q4-initial-take-a-strong-end-to-2025 https://www.redeye.se/research/1149167/devyser-q4-initial-take-a-strong-end-to-2025"
X Link 2026-02-12T09:13Z 14.4K followers, [---] engagements

"Redeye comments on RaySearch delivering a strong Q4 with record sales above consensus estimates and record EBIT also above consensus estimates. $RAY https://www.redeye.se/research/1149210/raysearch-laboratories-q4-initial-take-another-record-quarter https://www.redeye.se/research/1149210/raysearch-laboratories-q4-initial-take-another-record-quarter"
X Link 2026-02-12T09:44Z 14.4K followers, [---] engagements

"Redeye provides its first take on Camurus Q4 report [----] published this morning. $CAMX https://www.redeye.se/research/1149158/camurus-q4-initial-take-europe-continued-decline-us-growth https://www.redeye.se/research/1149158/camurus-q4-initial-take-europe-continued-decline-us-growth"
X Link 2026-02-12T09:46Z 14.4K followers, [---] engagements

"Redeye comments on Tradedoubler's Q4 report being impacted by a significant revaluation of the KaHa earnout liability which masked a relatively stable underlying performance. $TRAD https://www.redeye.se/research/1143265/tradedoubler-q4-initial-take-underlying-performance-largely-in-line https://www.redeye.se/research/1143265/tradedoubler-q4-initial-take-underlying-performance-largely-in-line"
X Link 2026-02-12T09:47Z 14.4K followers, [---] engagements

"Redeye provides its initial take on Ferroamps Q4 numbers which presented strong sales growth and significantly improved profitability y-o-y. $FERRO https://www.redeye.se/research/1149240/ferroamp-q4-initial-take-very-strong-sales-development https://www.redeye.se/research/1149240/ferroamp-q4-initial-take-very-strong-sales-development"
X Link 2026-02-12T09:48Z 14.4K followers, [---] engagements

"Redeye is encouraged by Nekkars financial recovery during the fourth quarter which posted a 30% beat on top-line and a [--] p.p stronger EBITDA margin compared to our relatively low set expectations. $NKR https://www.redeye.se/research/1148908/nekkar-q4-initial-take-better-than-expected https://www.redeye.se/research/1148908/nekkar-q4-initial-take-better-than-expected"
X Link 2026-02-12T09:48Z 14.4K followers, [---] engagements

"Redeye provides its initial take on Acarixs Q4 report which beat our topline estimates while costs were somewhat higher than we had anticipated. $ACARIX https://www.redeye.se/research/1149270/acarix-q4-inital-take-beat-on-topline https://www.redeye.se/research/1149270/acarix-q4-inital-take-beat-on-topline"
X Link 2026-02-12T09:49Z 14.4K followers, [---] engagements

"Redeye comments on Litiums Q4 which showed solid momentum with 18% ARR growth and net sales above our expectations. $LITI https://www.redeye.se/research/1148277/litium-q4-initial-take-record-order-intake https://www.redeye.se/research/1148277/litium-q4-initial-take-record-order-intake"
X Link 2026-02-12T09:50Z 14.4K followers, [---] engagements

"Redeye comments on Limes Q4 report showing 10% organic ARR growth slightly below our expectations. $LIME https://www.redeye.se/research/1148514/lime-q4-initial-take-slightly-below-expectations https://www.redeye.se/research/1148514/lime-q4-initial-take-slightly-below-expectations"
X Link 2026-02-12T09:51Z 14.4K followers, [---] engagements

"Redeye's immediate impression of Stille's year-end report [----] is positive. $STIL https://www.redeye.se/research/1146011/stille-q4-initial-take-beat-across-the-board-despite-fx-headwinds https://www.redeye.se/research/1146011/stille-q4-initial-take-beat-across-the-board-despite-fx-headwinds"
X Link 2026-02-12T09:51Z 14.4K followers, [---] engagements

"Redeye notes that as anticipated Genovis year-end report showcased robust top-line momentum with sharp sales growth following the SEK 11m ADC-order announced in Q4. $GENO https://www.redeye.se/research/1146004/genovis-q4-initial-take-in-line-with-our-estimates https://www.redeye.se/research/1146004/genovis-q4-initial-take-in-line-with-our-estimates"
X Link 2026-02-12T09:56Z 14.4K followers, [---] engagements

"Redeye considers Polygienes Q4'25 figures to be soft missing our expectations by 18% on top-line primarily driven by lower Polygiene sales. $POLYG https://www.redeye.se/research/1148755/polygiene-group-q4-initial-take-softer-than-expected https://www.redeye.se/research/1148755/polygiene-group-q4-initial-take-softer-than-expected"
X Link 2026-02-12T09:57Z 14.4K followers, [---] engagements

"Redeye comments on Hansa Biopharma's Q4 report. $HNSA https://www.redeye.se/research/1148786/hansa-biopharma-q4-update-strong-quarter-in-europe https://www.redeye.se/research/1148786/hansa-biopharma-q4-update-strong-quarter-in-europe"
X Link 2026-02-12T10:45Z 14.4K followers, [---] engagements

"Redeye keeps its positive view of Vertiseit following a decent Q4 report. $VERT https://www.redeye.se/research/1148498/vertiseit-q4-review-long-term-story-intact-ai-resilience-from-the-back-end https://www.redeye.se/research/1148498/vertiseit-q4-review-long-term-story-intact-ai-resilience-from-the-back-end"
X Link 2026-02-13T08:58Z 14.4K followers, [---] engagements

"Redeye comments on Tradedoubler's Q4 report showcasing solid underlying execution in a cautious market environment. $TRAD https://www.redeye.se/research/1143262/tradedoubler-q4-review-double-digit-metapic-single-digit-multiple https://www.redeye.se/research/1143262/tradedoubler-q4-review-double-digit-metapic-single-digit-multiple"
X Link 2026-02-13T09:01Z 14.4K followers, [---] engagements

"Redeye provides an update following Neola Medicals Q4 [----] report. $NEOLA https://www.redeye.se/research/1149522/neola-medical-q4-review-eyes-on-upcoming-clinical-data https://www.redeye.se/research/1149522/neola-medical-q4-review-eyes-on-upcoming-clinical-data"
X Link 2026-02-13T09:01Z 14.4K followers, [---] engagements

"Redeye updates on W5 Solutions following Q4 results that exceeded expectations. $W5 https://www.redeye.se/research/1149923/w5-solutions-q4-review-strong-year-end-and-positive-outlook https://www.redeye.se/research/1149923/w5-solutions-q4-review-strong-year-end-and-positive-outlook"
X Link 2026-02-13T09:02Z 14.4K followers, [---] engagements

"Redeye comments on Lytix' third quarter report [----]. $LYTIX https://www.redeye.se/research/1149495/lytix-biopharma-q4-review-well-funded-to-deliver-in-26 https://www.redeye.se/research/1149495/lytix-biopharma-q4-review-well-funded-to-deliver-in-26"
X Link 2026-02-13T09:02Z 14.4K followers, [---] engagements

"Redeye has interviewed Litium's CEO Martin Billenius who shares insights on the Q4 report the plans for [----] and the partnership with Monitor ERP. $LITI https://www.redeye.se/research/1149616/litium-q4-interview-redeye-speaks-with-ceo-martin-billenius https://www.redeye.se/research/1149616/litium-q4-interview-redeye-speaks-with-ceo-martin-billenius"
X Link 2026-02-13T09:04Z 14.4K followers, [---] engagements

"Redeye updates on Better Collective ahead of Q4-results (due [--] February after market close) where we expect a solid year-end performance supported by positive seasonality. $BETCO https://www.redeye.se/research/1149964/better-collective-q4-preview-solid-year-end-expected https://www.redeye.se/research/1149964/better-collective-q4-preview-solid-year-end-expected"
X Link 2026-02-13T09:04Z 14.4K followers, [---] engagements

"Redeye notes that Devyser delivered sales relatively in line with expectations but the star of the show was the excellent EBIT margin of 25% thanks to continued impressive cost control and returning Thermo Fisher sales. $DVYSR https://www.redeye.se/research/1149851/devyser-diagnostics-q4-review-jaw-dropping-ebit-margin https://www.redeye.se/research/1149851/devyser-diagnostics-q4-review-jaw-dropping-ebit-margin"
X Link 2026-02-13T09:06Z 14.4K followers, [---] engagements

"Redeye comments on Stilles soft share price developing over the past months to us appears more sentiment-driven than fundamental following the Q4 report. $STIL https://www.redeye.se/research/1148540/__trashed-2 https://www.redeye.se/research/1148540/__trashed-2"
X Link 2026-02-13T09:08Z 14.4K followers, [---] engagements

"Redeye views BeammWave's Q4 [----] report as a positive read with the share price likely to respond favourably to management's visible confidence better-than-expected cost discipline and continued momentum across all three customer verticals. $BEAMMW https://www.redeye.se/research/1149960/beammwave-q4-initial-take-execution-now-the-only-variable https://www.redeye.se/research/1149960/beammwave-q4-initial-take-execution-now-the-only-variable"
X Link 2026-02-13T09:08Z 14.4K followers, [---] engagements

"Redeye provides an update following Acarixs Q4 [----] report. $ACARIX https://www.redeye.se/research/1150002/acarix-q4-review-a-solid-end-to-2025 https://www.redeye.se/research/1150002/acarix-q4-review-a-solid-end-to-2025"
X Link 2026-02-13T09:09Z 14.4K followers, [---] engagements

"Redeye provides its initial take on Relais Q4 [----] report which featured an adjusted EBITA that aligned with our projection but a slightly soft organic growth amid a challenging market situation. $RELAIS https://www.redeye.se/research/1150093/relais-q4-initial-take-solid-profitability-softer-organic-growth https://www.redeye.se/research/1150093/relais-q4-initial-take-solid-profitability-softer-organic-growth"
X Link 2026-02-13T09:10Z 14.4K followers, [---] engagements

"Redeye sees Safetures Q4 [----] report to be another step in the right direction with positive ARR growth improving gross margin and solid cost control resulting in a positive EBIT. $SFTR https://www.redeye.se/research/1148745/safeture-q4-initial-take-sequential-improvements https://www.redeye.se/research/1148745/safeture-q4-initial-take-sequential-improvements"
X Link 2026-02-13T09:11Z 14.4K followers, [---] engagements

"Redeye has interviewed Invisios CEO Lars Hjgrd Hansen in connection with the company's Q4-results. $IVSO https://www.redeye.se/research/1150121/invisio-q4-interview-redeye-speaks-with-ceo-lars-hojgard-hansen https://www.redeye.se/research/1150121/invisio-q4-interview-redeye-speaks-with-ceo-lars-hojgard-hansen"
X Link 2026-02-13T09:39Z 14.4K followers, [---] engagements

"Redeye returns with an update on Sprint Bioscience following recent events and the Q4 report. $SPRINT https://www.redeye.se/research/1148578/sprint-bioscience-q4-review-promising-development https://www.redeye.se/research/1148578/sprint-bioscience-q4-review-promising-development"
X Link 2026-02-13T09:58Z 14.4K followers, [---] engagements

"Redeye has interviewed Acarix's CEO Aamir Mahmood following the release of the companys Q4 [----] report. $ACARIX https://www.redeye.se/research/1149628/acarix-q4-interview-redeye-speaks-with-ceo-aamir-mahmood https://www.redeye.se/research/1149628/acarix-q4-interview-redeye-speaks-with-ceo-aamir-mahmood"
X Link 2026-02-13T11:01Z 14.4K followers, [---] engagements

"Redeye comments on Active Biotech's fourth quarter report. $ACTI https://www.redeye.se/research/1150157/active-biotech-q4-review-tasqinimod-recruiting-again https://www.redeye.se/research/1150157/active-biotech-q4-review-tasqinimod-recruiting-again"
X Link 2026-02-13T11:10Z 14.4K followers, [---] engagements

"Redeye concludes that Litium delivered a strong Q4 with ARR growth of 18% including Geins and organic growth of 9%. $LITI https://www.redeye.se/research/1148574/litium-q4-review-adding-growth-to-the-basket-in-h2 https://www.redeye.se/research/1148574/litium-q4-review-adding-growth-to-the-basket-in-h2"
X Link 2026-02-13T14:47Z 14.4K followers, [---] engagements

"Redeye interviews Calliditas' CEO Rene Aguiar-Lucander after securing full FDA approval for Tarpeyo. $CALTX https://www.redeye.se/research/968342/calliditas-interview-with-ceo-renee-aguiar-lucander-2 https://www.redeye.se/research/968342/calliditas-interview-with-ceo-renee-aguiar-lucander-2"
X Link 2023-12-22T07:12Z 14.4K followers, [----] engagements

"Redeye har intervjuat Calliditas VD Rene Aguiar-Lucander fr ett samtal om utsikterna fr Tarpeyo. $CALTX https://www.redeye.se/research/999301/calliditas-intervju-med-vd-renee-aguiar-lucander https://www.redeye.se/research/999301/calliditas-intervju-med-vd-renee-aguiar-lucander"
X Link 2024-04-26T06:42Z 14.4K followers, [----] engagements

"Redeye comments on XVIVO's delayed launch being a setback for both XVIVO patients and specialist centers waiting to use the solution. $XVIVO https://www.redeye.se/research/1121170/xvivo-the-european-heart-launch-is-delayed-for-6-12-months https://www.redeye.se/research/1121170/xvivo-the-european-heart-launch-is-delayed-for-6-12-months"
X Link 2025-07-29T11:59Z 14.4K followers, [----] engagements

"Redeye addresses some of the identified short case arguments circulating Bonesupport and discusses the share price collapse of [----]. $BONEX https://www.redeye.se/research/1143815/bonesupport-addressing-circulating-short-seller-arguments https://www.redeye.se/research/1143815/bonesupport-addressing-circulating-short-seller-arguments"
X Link 2025-12-19T08:39Z 14.4K followers, [----] engagements

"Redeye comments on Avtech releasing their preliminary figures for Q4 [----] which fell short of Redeye expectations on both sales and EBITDA. $AVT https://www.redeye.se/research/1146122/avtech-q4-preliminary-figures-sales-miss-due-to-postponed-sales https://www.redeye.se/research/1146122/avtech-q4-preliminary-figures-sales-miss-due-to-postponed-sales"
X Link 2026-01-27T13:50Z 14.4K followers, [----] engagements

"Redeye notes that AVTECH's Q4 [----] results aligned with preliminary figures whilst falling short of the firm's estimates by 11% on sales and 10% on adjusted EBITDA. $AVT https://www.redeye.se/research/1147769/avtech-q4-initial-take-pre-announced-results-set-stage-for-modest-base-case-recalibration https://www.redeye.se/research/1147769/avtech-q4-initial-take-pre-announced-results-set-stage-for-modest-base-case-recalibration"
X Link 2026-02-06T08:29Z 14.4K followers, [---] engagements

"Redeye har intervjuat I-Techs vd Markus Jnsson angende Q4 rapporten. $ITECH https://www.redeye.se/research/1147207/i-tech-q4-intervju-redeye-pratar-med-vd-markus-jonsson https://www.redeye.se/research/1147207/i-tech-q4-intervju-redeye-pratar-med-vd-markus-jonsson"
X Link 2026-02-06T14:00Z 14.4K followers, [---] engagements

"Redeye revises its base case to SEK10(SEK12) following AVTECH's Q4 [----] results which fell 11% short on net sales owing to anticipated contracts failing to materialise. $AVT https://www.redeye.se/research/1148102/avtech-q4-review-40-de-rating-leads-to-increasingly-compelling-setup https://www.redeye.se/research/1148102/avtech-q4-review-40-de-rating-leads-to-increasingly-compelling-setup"
X Link 2026-02-09T08:58Z 14.4K followers, [---] engagements

"Redeye has interviewed AVTECHs CEO David Rytter to discuss the past year future development and the current sales pipeline. $AVT https://www.redeye.se/research/1147928/avtech-q4-interview-redeye-speaks-with-ceo-david-ritter https://www.redeye.se/research/1147928/avtech-q4-interview-redeye-speaks-with-ceo-david-ritter"
X Link 2026-02-09T09:02Z 14.4K followers, [---] engagements

"Redeye comments on Carasents Q4 report showing slightly lower organic ARR growth yet solid scalability. $CARA https://www.redeye.se/research/1148492/carasent-q4-initial-take-reaching-2025-targets https://www.redeye.se/research/1148492/carasent-q4-initial-take-reaching-2025-targets"
X Link 2026-02-12T09:11Z 14.4K followers, [---] engagements

"Redeye comments on Embracers Q3-results which were better than expected driven by solid results in PC/Console supported by strong back catalogue performance. $EMBRAC https://www.redeye.se/research/1149221/embracer-q3-initial-take-strong-results-guidance-in-line https://www.redeye.se/research/1149221/embracer-q3-initial-take-strong-results-guidance-in-line"
X Link 2026-02-12T09:46Z 14.4K followers, [---] engagements

"Redeye retains its positive view of CombinedX following a solid Q4 with strong underlying margins. $CX https://www.redeye.se/research/1148424/combinedx-q4-review-entering-2026-with-renewed-vision https://www.redeye.se/research/1148424/combinedx-q4-review-entering-2026-with-renewed-vision"
X Link 2026-02-13T08:59Z 14.4K followers, [---] engagements

"Redeye retains its positive view of Lime following the Q4 report. $LIME https://www.redeye.se/research/1148509/lime-q4-review-solid-fundamentals-despite-ai-squeeze https://www.redeye.se/research/1148509/lime-q4-review-solid-fundamentals-despite-ai-squeeze"
X Link 2026-02-13T09:00Z 14.4K followers, [---] engagements

"The Q4 report offered few surprises. Hexatronic reported net sales of [---] MSEK and EBITDA of [--] MSEK. Adjusted. http://fb.me/6VC2L2tta http://fb.me/6VC2L2tta"
X Link 2015-10-29T09:05Z 14.4K followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing